Search BRITE hierarchies

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
  L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
    L01 ANTINEOPLASTIC AGENTS
      L01E PROTEIN KINASE INHIBITORS
        L01EC B-Raf serine-threonine kinase (BRAF) inhibitors [DG:DG03159]
          L01EC01 Vemurafenib
            D09996  Vemurafenib (JAN/USAN/INN) <JP/US>

USP drug classification [BR:br08302]
  Antineoplastics
    Molecular Target Inhibitors
      Vemurafenib
        D09996  Vemurafenib (JAN/USAN/INN)

Therapeutic category of drugs in Japan [BR:br08301]
  4  Agents affecting cellular function
    42  Antineoplastics
      429  Miscellaneous
        4291  Other Antitumors
          D09996  Vemurafenib (JAN/USAN/INN)

Drug groups [BR:br08330]
  Antineoplastic
    DG03159  BRAF inhibitor
      D09996  Vemurafenib
  Metabolizing enzyme inhibitor
    DG01634  CYP1A2 inhibitor
      D09996  Vemurafenib
    DG01643  CYP2C9 inhibitor
      D09996  Vemurafenib
  Metabolizing enzyme inducer
    DG02853  CYP3A/CYP3A4 inducer
      DG01635  CYP3A4 inducer
        D09996  Vemurafenib
  Transporter inhibitor
    DG01622  ABCB1 inhibitor
      D09996  Vemurafenib

Drug classes [BR:br08332]
  Antineoplastic
    DG03159  BRAF inhibitor
      D09996  Vemurafenib

Target-based classification of drugs [BR:br08310]
  Protein kinases
    Serine/threonine kinases
      TKL group
        BRAF* [HSA_VAR:673v1] [HSA:673] [KO:K04365]
          D09996  Vemurafenib (JAN/USAN/INN) <JP/US>

New drug approvals in the USA [br08319.html]
  D09996

New drug approvals in Europe [br08329.html]
  D09996

New drug approvals in Japan [br08318.html]
  D09996

New drug approvals in the USA, Europe and Japan [br08328.html]
  D09996

Drug metabolizing enzymes and transporters [br08309.html]
  D09996

Pharmacogenomic biomarkers [br08341.html]
  D09996